T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions

Metastatic Breast Cancer

Interventions

DRUG

T-DM1

antibody-drug conjugate of trastuzumab and emtansine

DRUG

Lapatinib

Dual tyrosine kinase inhibitor (HER2 and EGFR)

DRUG

Abraxane

albumin-bound paclitaxel. Chemotherapy - microtubule inhibitor

Trial Locations (1)

Houston Methodist Hospital, Houston

All Listed Sponsors

collaborator

The Methodist Hospital Research Institute

OTHER

lead

Jenny C. Chang, MD

OTHER

NCT02073916 - T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer | Biotech Hunter | Biotech Hunter